MarketPeel
Insider Trading Intelligence
SP

Spyros Papapetropoulos

LPCN
DIRECTOR · LIPOCINE INC. · CIK 0001832694
FILING MIX · LIFETIME100%/0%
BUYS
9
SELLS
0
TOTAL VALUE
$1.89M
COMPANIES
2
ACTIVE SINCE
Apr 2022
HOLDINGS NOW
81,262
AVG SELL PX
TRADE KIND
SHOWING 9 / 9
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
1 backtested trades · 8 horizonsHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Spyros Papapetropoulos, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d1+0.00%-4.87%-1.17%-3.70%-3.70%
14d1+0.00%-9.78%-1.52%-8.26%-8.26%
30d1+0.00%-10.85%-4.36%-6.49%-6.49%
60d1+100.00%+17.39%-0.55%+17.94%+17.94%
90d1+100.00%+5.70%+0.26%+5.44%+5.44%
180d1+0.00%-48.08%+5.61%-53.69%-53.69%
1y1+0.00%-68.41%+15.57%-83.99%-83.99%
2y1+0.00%-36.06%+52.83%-88.89%-88.89%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
LPCN · 7,174 shares · as of Jun 4, 2025
015,50031,00046,50062,000202320242025SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
FLOW · 9 buys / 0 sellsCOVERAGE · 14 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
NEUP
NEUPHORIA THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
34,559$8.27$285.8K74,088Aug 27, 2025Sep 1, 2025View →
LPCN
LIPOCINE INC.
PURCHASEGRANT
Stock grant
1,764$3.20$5.6K7,174Jun 4, 2025Jun 5, 2025View →
NEUP
NEUPHORIA THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
270,000$5.16$1.39M282,529Apr 16, 2025Apr 17, 2025View →
NEUP
NEUPHORIA THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
27,000$5.16$139.3K39,529Apr 16, 2025May 19, 2025View →
LPCN
LIPOCINE INC.
PURCHASEGRANT
Stock grant
1,764$7.05$12.4K5,410Jun 5, 2024Jun 7, 2024View →
LPCN
LIPOCINE INC.
PURCHASEGRANT
Stock grant
30,000$0.27$8.0K62,000May 10, 2023May 12, 2023View →
LPCN
LIPOCINE INC.
PURCHASE
21,739$0.47$10.2K21,739Nov 22, 2022Nov 28, 2022View →
LPCN
LIPOCINE INC.
PURCHASEGRANT
Stock grant
22,000$0.92$20.2K32,000Jun 8, 2022Jun 10, 2022View →
LPCN
LIPOCINE INC.
PURCHASEGRANT
Stock grant
10,000$1.16$11.6K10,000Apr 11, 2022Apr 12, 2022View →
Other insiders · LPCN
Loading peer insiders…
About this filer
CIK 0001832694
ROLE
Director
PRIMARY
LPCN
COMPANIES
2
ACTIVE SINCE
Apr 2022
MARKETPEEL · /INSIDER/0001832694DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback